AstraZeneca plc ( via Public ) / AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial

A Covid-19 antibody given to patients with mild-to-moderate symptoms has reduced the risk of developing severe COVID-19 or death, according to a trial in the US and Canada. Trials have been carried out by AstraZeneca.

Source: publicnow.com
Published on 2021-10-12